ZBIO Stock Summary and Trading Ideas (Zenas Biopharma | NASDAQ:ZBIO)

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Zenas Biopharma trades on the NASDAQ stock market under the symbol ZBIO.

As of October 23, 2026, ZBIO stock price declined to $26.87 with 308,215 million shares trading.

ZBIO has a beta of -0.20, meaning it tends to be less sensitive to market movements. ZBIO has a correlation of 0.00 to the broad based SPY ETF.

ZBIO has a market cap of $1.75 billion. This is considered a Small Cap stock.

Last quarter Zenas Biopharma reported $1 million in Revenue and -$1.77 earnings per share. This fell short of revenue expectation by $-26 million and missed earnings estimates by -$.99.

The top ETF exchange traded funds that ZBIO belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

ZBIO has underperformed the market in the last year with a return of +7.4%, while the SPY ETF gained +14.3%. In the last 3 month period, ZBIO fell short of the market, returning -13.3%, while SPY returned +3.2%. However, in the most recent 2 weeks ZBIO has outperformed the stock market by returning -1.4%, while SPY returned -2.4%.

ZBIO support price is $27.05 and resistance is $29.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZBIO shares will trade within this expected range on the day.